Symbols / VAXX $0.01 +0.00% Vaxxinity, Inc.
VAXX Chart
About
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.
Fundamentals
Scroll to Statements| Market Cap | 1.27M | Enterprise Value | -15.46M | Income | -56.93M | Sales | — | Book/sh | 0.11 | Cash/sh | 0.24 |
| Dividend Yield | — | Payout | 0.00% | Employees | 57 | IPO | — | P/E | — | Forward P/E | -0.03 |
| PEG | — | P/S | — | P/B | 0.09 | P/C | — | EV/EBITDA | 0.28 | EV/Sales | — |
| Quick Ratio | 1.76 | Current Ratio | 1.89 | Debt/Eq | 113.12 | LT Debt/Eq | — | EPS (ttm) | -4.50 | EPS next Y | -0.38 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2023-11-08 | ROA | -48.34% | ROE | -150.65% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 112.91M | Shs Float | 112.87M | Short Float | 108.73% |
| Short Ratio | 13.97 | Short Interest | — | 52W High | 0.05 | 52W Low | 0.00 | Beta | -65.34 | Avg Volume | 13.02K |
| Volume | 257.00 | Target Price | — | Recom | None | Prev Close | $0.01 | Price | $0.01 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.01
Latest analyst target
3. DCF / Fair value
$-5.96
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.01
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-09-08 | init | Baird | — → Outperform | $7 |
| 2022-04-27 | init | Evercore ISI Group | — → In-Line | — |
| 2021-12-07 | init | Jefferies | — → Buy | $18 |
| 2021-12-06 | init | B of A Securities | — → Buy | $21 |
- AVMA launches resource to help veterinarians address pet vaccine hesitancy - DVM360 hu, 09 Apr 2026 07
- Net Worth Update: Senator Rick Scott Made an Estimated $3.1M in the Stock Market Last Month - Quiver Quantitative Sun, 12 Oct 2025 07
- The hottest cancer vaccine companies you should know about - Labiotech.eu Mon, 16 Mar 2026 07
- VAXX (Vaxxinity, NASDAQ) at $0.0075 on 19 Mar 2026: Earnings could change momentum - Meyka hu, 19 Mar 2026 07
- Planned US-funded baby vaccine trial in Guinea-Bissau blasted by WHO - BBC Sat, 14 Feb 2026 08
- Anti-vaccine group asks RFK Jr. to add more vaccine injuries to compensation program - Seeking Alpha hu, 26 Mar 2026 07
- Net Worth Update: Senator Rick Scott Made an Estimated $863.6K in the Stock Market Last Month - Quiver Quantitative Sun, 10 Aug 2025 07
- HSE vaccine wastage revealed as €48m of flu, Covid & HPV jabs binned or returned - The Irish Sun Sun, 19 Apr 2026 07
- VAXX Stock Price and Chart — OTC:VAXX - TradingView Sun, 12 May 2024 01
- Why Is Vaxxinity (VAXX) Stock Down 58% Today? - InvestorPlace Mon, 22 Apr 2024 07
- Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock - Yahoo Finance Fri, 19 Apr 2024 07
- Vaxxinity leaders detail retreat from 'abusive relationship' after 3 years on public market - Fierce Biotech Wed, 15 May 2024 07
- One vaccine may provide broad protection against many respiratory infections and allergens - Stanford Medicine hu, 19 Feb 2026 08
- Moderna: FDA RTF Derails mRNA-1010 And Reignites The Sell Case (NASDAQ:MRNA) - Seeking Alpha Wed, 11 Feb 2026 08
- Vaxxinity (VAXX) Stock Price, News & Analysis - MarketBeat Sat, 27 Nov 2021 00
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
-100.00%
|
0.07
|
| Operating Revenue |
|
0.00
|
0.00
-100.00%
|
0.07
|
| Cost Of Revenue |
|
—
|
0.00
-100.00%
|
1.94
|
| Reconciled Cost Of Revenue |
|
—
|
0.00
-100.00%
|
1.94
|
| Gross Profit |
|
—
|
0.00
+100.00%
|
-1.87
|
| Operating Expense |
|
58.28
-23.29%
|
75.98
-38.33%
|
123.20
|
| Research And Development |
|
35.90
-24.62%
|
47.63
-33.28%
|
71.38
|
| Selling General And Administration |
|
22.39
-21.04%
|
28.35
-45.29%
|
51.83
|
| General And Administrative Expense |
|
22.39
-21.04%
|
28.35
-45.29%
|
51.83
|
| Other Gand A |
|
22.39
-21.04%
|
28.35
-45.29%
|
51.83
|
| Total Expenses |
|
58.28
-23.29%
|
75.98
-39.29%
|
125.14
|
| Operating Income |
|
-58.28
+23.29%
|
-75.98
+39.25%
|
-125.08
|
| Total Operating Income As Reported |
|
-58.28
+23.29%
|
-75.98
+39.25%
|
-125.08
|
| EBITDA |
|
-54.00
+26.05%
|
-73.02
+46.00%
|
-135.23
|
| Normalized EBITDA |
|
-53.96
+26.12%
|
-73.04
+41.08%
|
-123.96
|
| Reconciled Depreciation |
|
2.23
+32.66%
|
1.68
+52.81%
|
1.10
|
| EBIT |
|
-56.24
+24.72%
|
-74.71
+45.20%
|
-136.34
|
| Total Unusual Items |
|
-0.04
-458.33%
|
0.01
+100.11%
|
-11.27
|
| Total Unusual Items Excluding Goodwill |
|
-0.04
-458.33%
|
0.01
+100.11%
|
-11.27
|
| Net Income |
|
-56.93
+24.31%
|
-75.22
+45.16%
|
-137.18
|
| Pretax Income |
|
-56.93
+24.31%
|
-75.22
+45.16%
|
-137.18
|
| Net Non Operating Interest Income Expense |
|
1.39
+87.11%
|
0.74
+189.65%
|
-0.83
|
| Interest Expense Non Operating |
|
0.70
+35.41%
|
0.51
-38.81%
|
0.84
|
| Net Interest Income |
|
1.39
+87.11%
|
0.74
+189.65%
|
-0.83
|
| Interest Expense |
|
0.70
+35.41%
|
0.51
-38.81%
|
0.84
|
| Interest Income Non Operating |
|
2.09
+66.00%
|
1.26
+13888.89%
|
0.01
|
| Interest Income |
|
2.09
+66.00%
|
1.26
+13888.89%
|
0.01
|
| Other Income Expense |
|
-0.04
-458.33%
|
0.01
+100.11%
|
-11.27
|
| Other Non Operating Income Expenses |
|
—
|
—
|
-8.37
|
| Gain On Sale Of Security |
|
-0.04
-458.33%
|
0.01
+100.11%
|
-11.27
|
| Tax Provision |
|
—
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-56.93
+24.31%
|
-75.22
+45.16%
|
-137.18
|
| Net Income From Continuing Operation Net Minority Interest |
|
-56.93
+24.31%
|
-75.22
+45.16%
|
-137.18
|
| Net Income From Continuing And Discontinued Operation |
|
-56.93
+24.31%
|
-75.22
+45.16%
|
-137.18
|
| Net Income Continuous Operations |
|
-56.93
+24.31%
|
-75.22
+45.16%
|
-137.18
|
| Normalized Income |
|
-56.89
+24.38%
|
-75.23
+40.25%
|
-125.91
|
| Net Income Common Stockholders |
|
-56.93
+24.31%
|
-75.22
+45.16%
|
-137.18
|
| Diluted EPS |
|
—
|
-0.60
+66.48%
|
-1.79
|
| Basic EPS |
|
—
|
-0.60
+66.48%
|
-1.79
|
| Basic Average Shares |
|
—
|
125.94
+64.44%
|
76.59
|
| Diluted Average Shares |
|
—
|
125.94
+64.44%
|
76.59
|
| Diluted NI Availto Com Stockholders |
|
-56.93
+24.31%
|
-75.22
+45.16%
|
-137.18
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
44.31
|
| Current Assets |
|
33.23
|
| Cash Cash Equivalents And Short Term Investments |
|
30.39
|
| Cash And Cash Equivalents |
|
4.93
|
| Other Short Term Investments |
|
25.46
|
| Receivables |
|
0.41
|
| Accounts Receivable |
|
—
|
| Prepaid Assets |
|
1.48
|
| Restricted Cash |
|
0.10
|
| Other Current Assets |
|
0.84
|
| Total Non Current Assets |
|
11.08
|
| Net PPE |
|
11.08
|
| Gross PPE |
|
16.95
|
| Accumulated Depreciation |
|
-5.87
|
| Properties |
|
0.00
|
| Machinery Furniture Equipment |
|
16.24
|
| Construction In Progress |
|
0.13
|
| Other Properties |
|
—
|
| Leases |
|
0.58
|
| Non Current Deferred Assets |
|
—
|
| Other Non Current Assets |
|
—
|
| Total Liabilities Net Minority Interest |
|
30.90
|
| Current Liabilities |
|
17.61
|
| Payables And Accrued Expenses |
|
14.14
|
| Payables |
|
12.36
|
| Accounts Payable |
|
1.78
|
| Current Accrued Expenses |
|
1.78
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
1.56
|
| Current Debt And Capital Lease Obligation |
|
1.91
|
| Current Debt |
|
1.91
|
| Other Current Borrowings |
|
0.41
|
| Total Non Current Liabilities Net Minority Interest |
|
13.30
|
| Long Term Debt And Capital Lease Obligation |
|
13.26
|
| Long Term Debt |
|
13.26
|
| Long Term Provisions |
|
—
|
| Non Current Deferred Liabilities |
|
0.04
|
| Non Current Deferred Taxes Liabilities |
|
0.04
|
| Preferred Securities Outside Stock Equity |
|
—
|
| Stockholders Equity |
|
13.41
|
| Common Stock Equity |
|
13.41
|
| Capital Stock |
|
0.28
|
| Common Stock |
|
0.28
|
| Preferred Stock |
|
—
|
| Share Issued |
|
126.75
|
| Ordinary Shares Number |
|
126.75
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
374.76
|
| Retained Earnings |
|
-361.64
|
| Gains Losses Not Affecting Retained Earnings |
|
0.01
|
| Treasury Stock |
|
—
|
| Other Equity Adjustments |
|
0.01
|
| Total Equity Gross Minority Interest |
|
13.41
|
| Total Capitalization |
|
26.67
|
| Working Capital |
|
15.62
|
| Invested Capital |
|
28.58
|
| Total Debt |
|
15.17
|
| Net Debt |
|
10.24
|
| Net Tangible Assets |
|
13.41
|
| Tangible Book Value |
|
13.41
|
| Current Notes Payable |
|
1.50
|
| Derivative Product Liabilities |
|
—
|
| Duefrom Related Parties Current |
|
0.41
|
| Dueto Related Parties Current |
|
10.57
|
| Interest Payable |
|
0.02
|
| Non Current Accrued Expenses |
|
—
|
| Line Item | Trend | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow |
|
-57.24
-2.34%
|
-55.93
+30.94%
|
-80.99
|
| Cash Flow From Continuing Operating Activities |
|
-57.24
-2.34%
|
-55.93
+30.94%
|
-80.99
|
| Net Income From Continuing Operations |
|
-56.93
+24.31%
|
-75.22
+45.16%
|
-137.18
|
| Depreciation Amortization Depletion |
|
2.23
+32.66%
|
1.68
+52.81%
|
1.10
|
| Depreciation |
|
2.23
+32.66%
|
1.68
+52.81%
|
1.10
|
| Depreciation And Amortization |
|
2.23
+32.66%
|
1.68
+52.81%
|
1.10
|
| Other Non Cash Items |
|
0.05
-3.77%
|
0.05
-98.35%
|
3.21
|
| Stock Based Compensation |
|
7.51
-13.84%
|
8.71
-71.35%
|
30.41
|
| Operating Gains Losses |
|
—
|
0.04
-99.50%
|
8.58
|
| Gain Loss On Investment Securities |
|
—
|
—
|
8.58
|
| Change In Working Capital |
|
-8.54
-186.98%
|
9.82
-23.77%
|
12.88
|
| Change In Receivables |
|
-0.00
+95.24%
|
-0.02
-320.00%
|
-0.01
|
| Changes In Account Receivables |
|
—
|
0.00
-100.00%
|
0.03
|
| Change In Prepaid Assets |
|
3.24
-1.94%
|
3.30
+170.15%
|
-4.70
|
| Change In Payables And Accrued Expense |
|
-11.58
-276.91%
|
6.54
-57.37%
|
15.35
|
| Change In Accrued Expense |
|
-8.03
-217.19%
|
6.85
+285.97%
|
1.77
|
| Change In Payable |
|
-3.55
-1055.70%
|
-0.31
-102.26%
|
13.58
|
| Change In Account Payable |
|
-3.51
-267.00%
|
2.10
-3.27%
|
2.17
|
| Change In Other Working Capital |
|
—
|
—
|
2.25
|
| Change In Other Current Liabilities |
|
-0.20
-20000.00%
|
-0.00
+91.67%
|
-0.01
|
| Investing Cash Flow |
|
28.84
+153.03%
|
-54.39
-4026.86%
|
-1.32
|
| Cash Flow From Continuing Investing Activities |
|
28.84
+153.03%
|
-54.39
-4026.86%
|
-1.32
|
| Net PPE Purchase And Sale |
|
-0.80
+56.97%
|
-1.87
-41.58%
|
-1.32
|
| Purchase Of PPE |
|
-0.80
+56.97%
|
-1.87
-41.58%
|
-1.32
|
| Capital Expenditure |
|
-0.80
+56.97%
|
-1.87
-41.58%
|
-1.32
|
| Net Investment Purchase And Sale |
|
29.65
+156.44%
|
-52.53
|
0.00
|
| Purchase Of Investment |
|
-63.94
+40.53%
|
-107.53
|
0.00
|
| Sale Of Investment |
|
93.59
+70.16%
|
55.00
|
0.00
|
| Financing Cash Flow |
|
-1.14
-582.63%
|
-0.17
-100.09%
|
196.17
|
| Cash Flow From Continuing Financing Activities |
|
-1.14
-582.63%
|
-0.17
-100.09%
|
196.17
|
| Net Issuance Payments Of Debt |
|
-1.59
-270.70%
|
-0.43
+44.23%
|
-0.77
|
| Issuance Of Debt |
|
—
|
0.00
-100.00%
|
2.00
|
| Repayment Of Debt |
|
-1.59
-270.70%
|
-0.43
+84.48%
|
-2.77
|
| Long Term Debt Issuance |
|
—
|
0.00
-100.00%
|
2.00
|
| Long Term Debt Payments |
|
-1.59
-270.70%
|
-0.43
+84.48%
|
-2.77
|
| Net Long Term Debt Issuance |
|
-1.59
-270.70%
|
-0.43
+44.23%
|
-0.77
|
| Net Common Stock Issuance |
|
—
|
0.00
-100.00%
|
71.08
|
| Proceeds From Stock Option Exercised |
|
0.45
+72.62%
|
0.26
+54.71%
|
0.17
|
| Net Other Financing Charges |
|
—
|
—
|
2.90
|
| Changes In Cash |
|
-29.53
+73.27%
|
-110.49
-197.04%
|
113.86
|
| Beginning Cash Position |
|
34.57
-76.17%
|
145.06
+364.96%
|
31.20
|
| End Cash Position |
|
5.04
-85.43%
|
34.57
-76.17%
|
145.06
|
| Free Cash Flow |
|
-58.04
-0.43%
|
-57.79
+29.78%
|
-82.31
|
| Interest Paid Supplemental Data |
|
0.80
+117.71%
|
0.37
-36.83%
|
0.58
|
| Amortization Of Securities |
|
-1.55
-52.05%
|
-1.02
|
0.00
|
| Common Stock Issuance |
|
—
|
0.00
-100.00%
|
71.08
|
| Issuance Of Capital Stock |
|
—
|
0.00
-100.00%
|
193.87
|
| Net Preferred Stock Issuance |
|
—
|
0.00
-100.00%
|
122.79
|
| Preferred Stock Issuance |
|
—
|
0.00
-100.00%
|
122.79
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|